- Molecular NameMiconazole
- SynonymMCZ; miconazole
- Weight416.135
- Drugbank_IDDB01110
- ACS_NO22916-47-8
- Show 2D model
- LogP (experiment)5.34
- LogP (predicted, AB/LogP v2.0)6.06
- pka6.7
- LogD (pH=7, predicted)5.95
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-5.58
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds6
- TPSA27.05
- StatusFDA approved
- AdministrationTopical, vaginal
- PharmacologyAn imidazole antifungal agent, developed by Janssen Pharmaceutica, and commonly applied topically (to the skin) or mucus membranes to cure fungal infections. It works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. It can also be used against certain species of Leishmania protozoa (which are a type of unicellular parasite), as these also contain ergosterol in their cell membranes. In addition to its antifungal and antiparasitic actions, it also has some limited antibacterial properties. It is marketed in various formulations under various brand names (see below).
- Absorption_value99.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability25.0
- Protein binding92.0
- Volume of distribution (VD)20 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half life24 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)LD50=3 gm/kg
- LD50 (mouse)LD50=3800 mg/kg